The HIV/AIDS epidemic in sub-Saharan Africa;Épidémie de sida en Afrique subsaharienne

Medecine/Sciences

Volumn 20, Issue 5, 2004, Pages 593-598

  Anglaret, Xavier ^a   Salamon, Roger ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CHEMOPROPHYLAXIS; DISEASE COURSE; EPIDEMIC; EPIDEMIOLOGICAL DATA; ERADICATION THERAPY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; REVIEW; AFRICA SOUTH OF THE SAHARA; INCIDENCE; PATHOPHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA SOUTH OF THE SAHARA; HIV INFECTIONS; HUMANS; INCIDENCE;

EID: 2442484673     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2004205593     Document Type: Review

References (59)

1. Onusida. Mise à jour des données épidé miologiques sur le VIH, décembre 2002, 38 pages. http://www.unaids.org/worldaidsday/2002/press/update/epiupdate2002_fr.doc
2. Onusida. Survol de l'épidémie dans le monde. Rapport sur l'épidémie mondiale de VIH/sida 2002, chapitre 2: 21-42.
3. Onusida. Rapport sur l'épidémie mondiale de VIH/sida 2002. 214 pages. http://www.unaids.org/barcelona/presskit/french/barcelana repart/contents_html.html
4. Buvé A, Bishikwabo-Nsarhaza K, Mutangadura G. The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet 2002; 359: 2001-17.
5. Zhu T, Korber B, Nahmias A, et al. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998; 391: 594-7.
6. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000; 288: 1789-96.
7. Quinn T. Global burden of the HIV pandemic. Lancet 1996; 348: 99-106.
8. Peeters M, Sharp P. Genetic diversity of HIV-1: The moving target. AIDS 2000; 14: 129-40.
9. Buvé A, Caraël M, Hayes R, et al. The multicentre study on factors determining the differential spread of HIV in four African cities: Summary and conclusions. AIDS 2001; 15: 127-31.
10. Banque mondiale. Rapport sur le développement dans le monde 1993: investir dans la santé. Paris, 1993, 340 p.
11. Djomand G, Greenberg AE, Sassan-Morokro M, et al. The epidemic of HIV/AIDS in Abidjan, Côte d'Ivoire: A review of data collected by projet RETRO-Cl from 1987 to 1993. J Acquir Immune Def Syndr Hum Retrovir 1995; 10: 358-65.
12. Anglaret X, Gnangbomon J, Coulibaly-Koné S, et al. Clinical and immunological stages of HIV-infected patients attending community clinics, Abidjan, Côte d'Ivoire. Int J STD AIDS 1998; 9: 432-3.
13. Grant A, Djomand G, Smets P, et al. Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Côte d'Ivoire. AIDS 1997; 11: 1357-64.
14. Kamanfu G, Mlika-Calbanne N, Girard P, et al. Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi. Am Rev Respir Dis 1993; 147: 658-63.
15. Brindle RJ, Nunn PP, Batchelor BI, et al. Infection and morbidity in patients with tuberculosis in Nairobi, Kenya. AIDS 1993; 7: 1469-74.
16. Clerinx J, Bogaerts J, Taelman H, et al. Chronic diarrhoea among adults in Kigali, Rwanda: association with bacterial enteropathogens, rectocolonic inflammation, and human immunodeficiency virus infection. Clin Infect Dis 1995; 21: 1282-4.
17. Malin A, Gwanzura L, Klein S, et al. Pneumocystis carinii pneumonia in Zimbabwe. Lancet 1995; 346: 1258-61.
18. Daley C, Mugusi F, Chen L, et al. Pulmonary complications of HIV infection in Dar es Salaam, Tanzania. Role of bronchoscopy and bronchoalveolar lavage. Am J Respir Crit Care Med 1996; 154: 105-10.
19. Jones N, Huebner R, Khoosal M, et al. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12: 2177-84.
20. Archibald L, McDonald L, Nwanyanwu O, et al. A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy. J Infect Dis 2000; 181: 1414-20.
21. Batungwanayo J, Taelman H, Allen S, et al. Pleural effusion, tuberculosis and HIV-1 infection in Kigali, Rwanda. AIDS 1993; 7: 73-9.
22. Batungwanayo J, Taelman H, Lucas S, et al. Pulmonary disease associated with the human immunodeficiency virus in Kigali, Rwanda: a fibre optic bronchoscopic study of 111 cases of undetermined etiology. Am J Respir Crit Care Med 1994; 6: 1591-6.
23. Gilks C, Brindle R, Otieno L, et al. Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet 1990; 346: 545-9.
24. Scott J, Hall A, Muyodi C, et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000; 355: 1225-30.
25. Vugia DJ, Kiehlbauch JA, Yeboue K, et al. Pathogens and predictors of fatal septicemia associated with the human immunodeficiency virus infection in Ivory Coast, West Africa. J Infect Dis 1993; 168: 564-70.
26. Mwachari C, Batchelor B, Paul J, et al. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. J Infect 1998; 37: 48-53.
27. Germani Y, Minssart P, Vohito M, et al. Etiologies of acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African republic, in relation to human immunodeficiency virus serostatus. Am J Trop Med Hyg 1998; 59: 1008-14.
28. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993; 7: 1569-79.
29. Leroy V, Msellati P, Lepage P, et al. Natural history of HIV-1 infection in African women: a prospective cohort study in Kigali, Rwanda, 1988-1993. J Acquir Immune Def Syndr 1995; 9: 415-21.
30. Gilks C, Ojoo S, Brindle R, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347: 718-23.
31. French N, Nakiyingi J, Carpenter L, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106-11.
32. Perriëns JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaïre. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-84.
33. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am J Med 1992; 146: 1439-44.
34. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocytes counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet 1995; 345: 607-10.
35. Morgan D, Maude G, Malambra S, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet 1997; 350: 245-50.
36. Sewankambo N, Gray R, Ahmad S, et al. Mortality associated with HIV infection in rural Rakai District, Uganda. AIDS 2000; 14: 2391-400.
37. French N, Mujugira A, Nakiyingi J, et al. Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. J Acquir Immune Def Syndr 1999; 22: 509-16.
38. Malamba S, Morgan D, Clayton T, et al. The prognostic value of the World health organisation staging system for HIV infection and disease in rural Uganda. AIDS 1999; 13: 2555-62.
39. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosppression on malaria parasitemia and clinical episodes in adults in rural Uganda. Lancet 2000; 356: 1051-6.
40. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimetoprim-sulphamethoxazole for HIV-1 infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353: 1462-8.
41. Anglaret X, Messou E, Ouassa T, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis, Abidjan, Côte d'Ivoire. AIDS 2003; 17: 575-84.
42. De Cock K, Chaisson R. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3: 457-65.
43. Whalen C, Jonhson J, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 801-8.
44. Unaids/WHO. Preventive therapy against tuberculosis in people living with HIV. Wkly Epidemiol Rec 1999; 74: 385-400.
45. Quigley M, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-22.
46. Fitzgerald D, Desvarieux M, Severe P, et al. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356: 1470-4.
47. Wiktor S, Sassan-Morokro M, Grant A, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-75.
48. Unaids/WHO. Provisional WHO/Unaids secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. 2000: http://www.unaids.org/publications/documents/care/general/recommendation-eng.pdf
49. Anglaret X, Dabis F, Batungwanayo J, et al. Chimioprophylaxie primaire de la tuberculose chez les séropositifs dans les pays non industrialisés. Santé 1997; 7: 89-94.
50. Boeree M, Harries A, Zijlstra E, et al. Co-trimoxazole in HIV-1 infection. Lancet 1999; 354: 334.
51. Iyer J, Milhous W, Cortese J, et al. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 2001; 358: 1066-7.
52. Martin J, Rose D, Hadley W, et al. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis 1999; 180: 1809-18.
53. Anglaret X. Cotrimoxazole prophylaxis in sub-Saharan Africa. Lancet 2001; 358: 1027-8.
54. Weidle P, Malamba S, Mwebaze R, et al. Asessment of a pilot antiretroviral drugs therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360: 34-40.
55. Laurent C, Diakhate N, Gueye N, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16: 1363-70.
56. Seyler C, Anglaret X, Dokoury-Dogbo N, et al. Medium-term survival, morbidity, and immuno-virological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther 2003; 8: 385-93.
57. Race E, Adelson-Mitty J, Kriegel G, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252-5.
58. French M, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1: 107-15.
59. Heath K, Singer J, O'Shoughnessy M, et al. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Def Syndr 2002; 31: 211-7.